Dr. Davies discusses data from CheckMate-274 study of nivolumab in urothelial carcinoma
"I think that for patients that have high-risk features after cystectomy, they absolutely should be on nivolumab. I don't think that's a controversial statement anymore," says Benjamin J. Davies, MD.
In this video, Benjamin J. Davies, MD, discusses findings from the study, Disease-free survival with longer follow-up from the CheckMate-274 trial of adjuvant nivolumab in patients after surgery for high-risk muscle-invasive urothelial carcinoma, which was presented at the 2022 American Urological Association Annual Meeting in New Orleans, Louisiana. Davies is a professor of urology at the University of Pittsburgh School of Medicine, chief of urology at UPMC Shadyside, and program director of the Urologic Oncology Fellowship.
Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app
December 7th 2021“It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.
Nadofaragene firadenovec shows durable efficacy in NMIBC
April 8th 2024"In this follow-up analysis of the phase 3 study, we demonstrated a sustained response to Adstiladrin treatment over 3 years, allowing more than half of the patients in the study to remain cystectomy free for at least 36 months,” says Colin P.N. Dinney, MD.
